Comprehensive Report: Mometasone Furoate (DB14512)

Executive Summary

Mometasone Furoate (DrugBank ID: DB14512) is a potent, synthetic, small-molecule glucocorticoid that has become a cornerstone therapy for a range of inflammatory conditions affecting the skin, nasal passages, and airways. Its clinical utility and commercial success are predicated on a meticulously engineered molecular structure that provides a high therapeutic index, characterized by strong local anti-inflammatory activity coupled with deliberately low systemic bioavailability. This profile minimizes the risk of systemic adverse effects commonly associated with corticosteroid therapy.

The drug is formulated for three distinct routes of administration, each targeting a specific set of indications. As a topical agent (e.g., Elocon®), it is a medium-to-high potency treatment for corticosteroid-responsive dermatoses such as eczema and psoriasis. As a nasal spray (e.g., Nasonex®), it is a first-line therapy for the treatment and prophylaxis of allergic rhinitis and the management of nasal polyps. As an inhaled powder or aerosol (e.g., Asmanex®), it serves as a maintenance therapy for the prevention of asthma symptoms.

Pharmacologically, Mometasone Furoate functions as a high-affinity agonist of the glucocorticoid receptor, with a binding affinity approximately 22 times that of dexamethasone. Its mechanism involves the classic genomic pathways of steroid action: transactivation of anti-inflammatory genes and transrepression of pro-inflammatory transcription factors like NF-κB, leading to potent anti-inflammatory, antipruritic, and vasoconstrictive effects.

The pharmacokinetic profile is dominated by low systemic absorption from the site of application, a key safety feature. Any fraction of the drug that enters systemic circulation is extensively metabolized by the hepatic Cytochrome P450 3A4 (CYP3A4) enzyme system. This metabolic pathway is the basis for its most significant drug-drug interactions, particularly with potent CYP3A4 inhibitors (e.g., ketoconazole, ritonavir), which can increase systemic exposure and the risk of adverse effects.

Developed by Schering-Plough and first patented in 1981, Mometasone Furoate has had a significant market presence for decades. The journey to generic competition, especially for the Nasonex® nasal spray, spurred innovation in regulatory science, leading to the acceptance of novel in vitro bioequivalence methods for locally acting drugs. This report provides a comprehensive analysis of Mometasone Furoate, detailing its chemical properties, pharmacological mechanisms, comparative pharmacokinetics, extensive clinical trial evidence, robust safety profile, and its regulatory and commercial history.

Drug Identification and Physicochemical Properties

A precise understanding of a drug's identity and physical characteristics is fundamental to appreciating its formulation, biological activity, and therapeutic application. Mometasone Furoate is well-characterized across multiple chemical and regulatory databases.

[Nomenclature and Identifiers]

The compound is almost exclusively used in its esterified form in medical products, a critical distinction for nomenclature.[1]

• Primary Name: Mometasone Furoate [1]
• Parent Compound: Mometasone [1]
• DrugBank IDs: DB14512 (Mometasone Furoate); DB00764 (Mometasone) [1]
• CAS Numbers: 83919-23-7 (Mometasone Furoate); 105102-22-5 (Mometasone) [1]
• Synonyms and Development Codes: The compound is known by several synonyms, including Mometasone Furoate Anhydrous. Its development codes, SCH 32088 and SCH-32088, reflect its origin within the Schering-Plough research and development pipeline.[2]
• Chemical Class: Mometasone Furoate is classified as a synthetic corticosteroid and a member of the glucocorticoid class. Structurally, it is a pregnane steroid, specifically defined as a 2-furoate ester, an 11beta-hydroxy steroid, a 20-oxo steroid, an organochlorine compound, and a 3-oxo-Delta(1),Delta(4)-steroid.[3]

[Chemical Structure and Properties]

The physicochemical properties of Mometasone Furoate are integral to its potent local action and favorable safety profile.

• Chemical Formula: C27​H30​Cl2​O6​ [2]
• Molecular Weight: The average molecular weight is 521.43 g/mol, with a monoisotopic mass of 520.141944106 Da.[2]
• Structural Representation: The unambiguous chemical structure is defined by the following identifiers:
• SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CCl)OC(=O)C5=CC=CO5)C)O)Cl)C [1]
• InChI Key: WOFMFGQZHJDGCX-ZULDAHANSA-N [4]
• Physical Appearance and Properties: It presents as a white to off-white or light yellow crystalline powder.[5] It has a defined melting point range of 212.0 to 216.0 °C and is soluble in dimethyl sulfoxide (DMSO) at concentrations of at least 20 mg/mL.[5]
• Purity: As a pharmaceutical agent, it is produced to a high degree of purity, typically specified as ≥98% or ≥99% as determined by high-performance liquid chromatography (HPLC).[4]

[Structure-Function Relationship]

The clinical success of Mometasone Furoate is not accidental but rather the result of deliberate molecular engineering. The specific chemical modifications to the parent steroid backbone—the addition of a furoate ester at the 17α position and chlorine atoms at positions 9 and 21—are pivotal to its pharmacological profile. These substitutions were designed to optimize the balance between local efficacy and systemic safety.[10]

The addition of these functional groups, particularly the furoate ester, significantly increases the lipophilicity of the molecule.[10] This enhanced lipophilicity is a critical feature that governs its behavior at the site of application. For topical formulations, it allows the drug to more effectively permeate the stratum corneum of the skin. For all formulations, it facilitates diffusion across cellular membranes to reach the intracellular glucocorticoid receptors. This allows a high concentration of the drug to be achieved locally at the target tissue, which in turn enables potent anti-inflammatory effects at relatively low administered doses.[10]

Concurrently, these structural modifications contribute to the drug's favorable safety profile. The ester linkage at the 17-position serves as a metabolic "soft spot." Should the drug be absorbed into the systemic circulation, this bond is readily cleaved by esterase enzymes, particularly during first-pass metabolism in the liver. This rapid biotransformation into less active or inactive metabolites is a primary reason for the drug's very low systemic bioavailability.[10] Therefore, the chemical structure itself is the key to decoupling high local potency from the risk of systemic corticosteroid toxicity, representing a paradigm of rational drug design.

Pharmacology and Mechanism of Action

Mometasone Furoate exerts its therapeutic effects through potent and selective interactions with intracellular steroid receptors, leading to the modulation of gene expression and a subsequent reduction in the inflammatory cascade.

[Molecular Targets and Receptor Binding]

The potency of Mometasone Furoate is rooted in its high affinity for its primary molecular target.

• Primary Target: Glucocorticoid Receptor (GR): Mometasone Furoate is a powerful agonist of the GR.[2] Its affinity for this receptor is exceptionally high and serves as a key differentiator from other corticosteroids. Multiple sources report that its GR binding affinity is 22 times stronger than that of the potent steroid dexamethasone and exceeds that of many other corticosteroids, including fluticasone propionate and budesonide.[2] This high-affinity binding ensures robust receptor activation even at the low local concentrations achieved with therapeutic dosing.
• Secondary Target: Progesterone Receptor (PR): The drug also functions as a modulator of the progesterone receptor.[2] While its GR activity is dominant, this interaction with the PR suggests it is a less specific glucocorticoid than some comparators, such as fluticasone propionate.[4] The precise clinical implications of this PR activity are not fully elucidated but represent an important aspect of its complete pharmacological profile.
• Selectivity: A crucial aspect of its safety profile is its high selectivity for the GR over the mineralocorticoid receptor (MR). Compared to endogenous corticosteroids like cortisol, Mometasone Furoate has a much lower affinity for the MR.[2] This selectivity minimizes the risk of MR-mediated side effects, such as sodium and water retention, hypertension, and hypokalemia, which can be problematic with less selective steroids.

[Cellular and Genomic Mechanisms of Action]

Like all glucocorticoids, Mometasone Furoate acts primarily by altering the transcription of target genes.

• Intracellular Pathway: Owing to its lipophilic nature, the molecule readily diffuses across the plasma membrane of target cells (e.g., epithelial cells, eosinophils, mast cells) and into the cytoplasm.[1] In the cytosol, it binds to its cognate GR, which is typically held in an inactive state within a multiprotein complex containing heat shock proteins.
• Nuclear Translocation and Gene Regulation: Binding of Mometasone Furoate induces a conformational change in the GR, causing the release of the associated proteins. The activated drug-receptor complex then dimerizes and translocates into the cell nucleus.[2] Once inside the nucleus, the dimer binds to specific DNA sequences known as Glucocorticoid Response Elements (GREs) located in the promoter regions of steroid-responsive genes.[2] This interaction leads to two primary modes of gene regulation:

1. Transactivation: The GR complex acts as a transcription factor to increase the synthesis of anti-inflammatory proteins. A key example is the induction of annexin A1 (also known as lipocortin-1) and other phospholipase A2 (PLA2) inhibitory proteins.[1] By inhibiting PLA2, the drug blocks the release of arachidonic acid from membrane phospholipids, thereby halting the production of a wide array of downstream inflammatory mediators, including prostaglandins and leukotrienes.[3]
2. Transrepression: The activated GR complex can also suppress inflammation by interfering with the activity of other transcription factors, notably Activator Protein-1 (AP-1) and Nuclear Factor kappa-B (NF-κB).[2] NF-κB is a master regulator of the inflammatory response, driving the expression of numerous pro-inflammatory genes. By inhibiting NF-κB, Mometasone Furoate effectively downregulates the production of critical inflammatory molecules, including cytokines (e.g., Interleukin-4, IL-4; Interleukin-5, IL-5), chemokines, and cellular adhesion molecules that are central to the allergic and inflammatory response.[2]

[Pharmacodynamic Effects]

The sum of these molecular and cellular actions translates into a broad range of clinically relevant pharmacodynamic effects. Mometasone Furoate exhibits potent anti-inflammatory, antipruritic (anti-itch), and vasoconstrictive properties.[1] By inhibiting the production of inflammatory mediators and suppressing the recruitment and activation of inflammatory cells like mastocytes, eosinophils, and neutrophils, it effectively dampens the allergic and inflammatory response at the site of application.[1] This leads to the stabilization of cellular membranes, reduced capillary permeability, and ultimately, the alleviation of symptoms such as redness, swelling, itching, and mucus production.[1]

The following table provides a quantitative comparison of the glucocorticoid receptor binding affinity, illustrating the high potency of Mometasone Furoate.

Drug	Relative Binding Affinity for GR (Dexamethasone = 1.0)	Source
Mometasone Furoate	22.0	2
Dexamethasone	1.0	2
Fluticasone Propionate	18.0	13
Budesonide	9.4	(General knowledge from pharmacology)
Hydrocortisone	0.1	1

Note: Relative binding affinities can vary based on assay conditions. The values presented are for comparative illustration based on available data.

Pharmacokinetics: A Comparative Analysis by Formulation

The pharmacokinetic profile of Mometasone Furoate is fundamentally defined by its route of administration and is the cornerstone of its clinical success. Across its topical, nasal, and inhaled formulations, the overarching principle is to achieve high local drug concentrations for maximal therapeutic effect while ensuring minimal systemic absorption to enhance its safety profile.[10] Any portion of the drug that is swallowed, particularly after nasal or oral inhalation, undergoes extensive first-pass metabolism in the liver, further limiting systemic exposure.[11]

[Inhaled Formulation (e.g., Asmanex®)]

This route results in the highest systemic bioavailability among the three formulations, a key consideration for assessing potential systemic effects.

• Absorption & Bioavailability: Following oral inhalation, peak plasma concentrations (Tmax​) are achieved relatively quickly, within 1.0 to 2.5 hours.[2] There is a notable discrepancy in reported bioavailability values. Early single-dose studies, likely limited by assay sensitivity, reported a bioavailability of less than 1%.[2] However, more recent data from repeat-dose studies, which allow for drug accumulation to detectable levels, provide a more clinically relevant estimate of systemic bioavailability of approximately 11%.[2] This value is comparable to that of other inhaled corticosteroids like fluticasone propionate.[13]
• Distribution: For the systemically absorbed fraction, the drug distributes widely, with a steady-state volume of distribution (Vd​) of 152 L.[2]
• Metabolism & Excretion: The terminal elimination half-life (t1/2​) is approximately 5 to 5.8 hours.[2] Elimination of an inhaled dose occurs primarily through the feces (~74%) via biliary excretion of metabolites, with a minor fraction (~8%) excreted in the urine.[2]

[Nasal Formulation (e.g., Nasonex®)]

The nasal formulation is designed for maximal local action with negligible systemic uptake.

• Absorption & Bioavailability: Systemic bioavailability following intranasal administration is exceptionally low, consistently reported as less than 1% and often less than 0.5%.[14] Plasma concentrations are frequently described as "virtually undetectable" even when using highly sensitive assays with a lower limit of quantitation of 50 pg/mL.[15] This extremely low systemic exposure is a primary safety feature, allowing for chronic use in conditions like perennial allergic rhinitis with minimal risk of systemic corticosteroid side effects.[11]
• The Regulatory Challenge and Innovation for Locally Acting Drugs: The very success of the nasal formulation in minimizing systemic absorption posed a significant regulatory hurdle for the approval of generic versions. The standard method for demonstrating bioequivalence between a generic and a brand-name drug relies on pharmacokinetic studies that measure and compare drug concentrations (e.g., Cmax​ and AUC) in the bloodstream of healthy volunteers. Because Mometasone Furoate from nasal spray is virtually undetectable in plasma, this traditional pathway was not viable.[15] This impasse effectively delayed generic competition for years. To overcome this, the U.S. Food and Drug Administration (FDA), in collaboration with industry, pioneered a "weight-of-evidence" approach.[16] This new paradigm shifted the focus from in vivo blood-level studies to a comprehensive suite of in vitro analyses designed to demonstrate pharmaceutical equivalence. This included the use of advanced analytical techniques like Morphologically-Directed Raman Spectroscopy (MDRS), which can meticulously compare the particle size distribution, shape, and chemical identity of the active ingredient within the suspension formulation itself.[16] The landmark approval of the first generic Nasonex in 2016, based on this innovative approach, set a new and important precedent for the regulatory evaluation of complex, locally acting drug products with low systemic absorption.[16]

[Topical Formulation (e.g., Elocon®)]

Similar to the nasal spray, topical formulations are designed to keep the drug localized in the skin.

• Absorption & Bioavailability: Percutaneous absorption is minimal under normal conditions. Studies with the 0.1% ointment indicate a systemic bioavailability of approximately 0.4% to 0.7%.[2]
• Influencing Factors: Systemic absorption from topical application is not static and can be significantly increased by several factors. These include application to large surface areas of the body, prolonged duration of use, and disruption of the stratum corneum barrier due to inflammation or skin disease.[17] The use of occlusive dressings, such as bandages or tight-fitting plastic pants over a diaper in infants, can dramatically increase percutaneous absorption and the risk of systemic toxicity.[17] This variability underscores the importance of proper patient counseling on application technique.

[General Pharmacokinetic Parameters]

The following parameters apply to the fraction of Mometasone Furoate that is systemically absorbed, regardless of the initial route of administration.

• Protein Binding: Once in the bloodstream, Mometasone Furoate is highly bound to plasma proteins, with in vitro studies showing a binding of 98% to 99% over a concentration range of 5 to 500 ng/mL.[2]
• Metabolism: The drug undergoes extensive hepatic metabolism. The primary enzyme responsible for its biotransformation is Cytochrome P450 3A4 (CYP3A4).[2] This process generates multiple metabolites, including 6-beta-hydroxy-mometasone furoate and the parent compound, mometasone.[2] Importantly, there are no major metabolites detectable in plasma, suggesting that the metabolites are either formed in small quantities or cleared rapidly.[15]
• Clearance: Reflecting its rapid metabolism, the systemic clearance of Mometasone Furoate is high, estimated to be approximately 90 L/h.[2]

[Summary of Key Pharmacokinetic Parameters by Formulation]

Parameter	Inhaled Formulation	Nasal Formulation	Topical Formulation	Source(s)
Systemic Bioavailability	~11% (repeat dose)	<1% (virtually undetectable)	~0.4–0.7%	2
Tmax​ (hours)	1.0–2.5	Not applicable (N/A)	N/A	2
Volume of Distribution (Vd​)	152 L	N/A	N/A	2
Terminal Half-Life (t1/2​)	~5–5.8 hours	N/A	N/A	2
Primary Route of Excretion	Feces (~74%), Urine (~8%)	Primarily unabsorbed	Primarily unabsorbed	2

Clinical Efficacy and Therapeutic Applications

Mometasone Furoate's versatility is demonstrated by its successful formulation and approval for a diverse range of inflammatory conditions across dermatology, rhinology, and pulmonology.

[Topical Formulations (e.g., Elocon® 0.1% Cream, Ointment, Lotion)]

In dermatology, Mometasone Furoate is valued for its potent anti-inflammatory action.

• Indications: The 0.1% formulations are indicated for the relief of the inflammatory and pruritic (itchy) manifestations of corticosteroid-responsive dermatoses. This broad category includes conditions such as atopic dermatitis (eczema), psoriasis, and seborrheic dermatitis.[1]
• Potency: It is classified as a medium-to-high potency topical corticosteroid.[1] Pharmacodynamic studies have shown that it possesses greater anti-inflammatory activity and a longer duration of action than other commonly used steroids like betamethasone.[10] The ointment formulation is generally considered more potent than the cream or lotion.[17]
• Approved Population: The cream and ointment are approved for use in adults and pediatric patients two years of age and older.[2] The lotion formulation is typically approved for patients 12 years and older.[20] Use in children under the age of two is not recommended due to a higher risk of systemic absorption and potential side effects.[19]

[Nasal Formulations (e.g., Nasonex®, Ryaltris®)]

Intranasal Mometasone Furoate is a first-line treatment for inflammatory conditions of the nasal passages.

• Indications:
• Allergic Rhinitis: It is widely indicated for the treatment of nasal symptoms (e.g., rhinorrhea, sneezing, itching, congestion) of both seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR) in adults and children aged two years and older.[1]
• Prophylaxis of Seasonal Allergic Rhinitis: It is also approved for the prophylaxis (prevention) of SAR symptoms in adults and adolescents 12 years of age and older. For this use, treatment is initiated two to four weeks prior to the anticipated start of the pollen season.[2]
• Nasal Polyps: It is indicated for the treatment of nasal polyps in adults 18 years of age and older.[2]
• Clinical Trial Evidence: The efficacy of nasal Mometasone Furoate is supported by an extensive body of clinical trial data.
• Allergic Rhinitis: Numerous Phase 3 and 4 trials have established its superiority over placebo and non-inferiority or equivalence to other intranasal steroids. Studies like NCT00783224 directly compared it to fluticasone propionate for PAR.[28] Trials NCT00733005 and NCT00728416 confirmed its efficacy in relieving nasal congestion in SAR.[29] Onset-of-action studies demonstrated a clinically significant improvement in symptoms within 11 to 12 hours of the first dose.[24] Furthermore, patient preference studies (e.g., NCT00817050) showed a preference for the unscented Nasonex® formulation over a scented fluticasone spray.[31]
• Nasal Polyps: Phase 3 trials such as NCT00731185 and NCT01386125 have demonstrated its effectiveness in reducing polyp size and improving symptoms in adult patients, including those who have had previous sinus surgery.[32] Its established efficacy and safety have also led to its use as a standard-of-care background therapy in clinical trials evaluating novel biologic agents like mepolizumab (NCT03085797) and benralizumab (NCT03401229) for severe nasal polyposis.[32]
• Combination Products: Reflecting a trend toward multi-mechanism therapies, Mometasone Furoate is a key component in fixed-dose combination nasal sprays. Ryaltris® combines it with the antihistamine olopatadine, and other combinations with the antihistamine azelastine have also been studied (NCT01470053).[1] These products offer the convenience of a single device to target both the early-phase (histamine-driven) and late-phase (inflammatory) aspects of the allergic response.

[Inhaled Formulations (e.g., Asmanex® Twisthaler®/HFA®, Dulera®)]

In pulmonology, Mometasone Furoate is used as a controller medication for persistent asthma.

• Indication: It is indicated for the maintenance treatment of asthma as prophylactic therapy.[1]
• Crucial Limitation: A critical point for patient safety and education is that inhaled Mometasone Furoate is not a rescue inhaler and is not indicated for the relief of acute bronchospasm or an asthma attack that has already started.[34] Patients must have a separate short-acting beta-agonist (e.g., albuterol) for acute symptom relief.
• Approved Populations and Devices:
• Asmanex® Twisthaler®: This is a dry powder inhaler (DPI) approved for patients four years of age and older. It is available in a 110 mcg strength for children aged 4-11 and a 220 mcg strength for patients 12 and older.[34]
• Asmanex® HFA®: This is a hydrofluoroalkane-propelled metered-dose inhaler (MDI) approved for patients five years of age and older. It is available in a 50 mcg strength for children aged 5 to less than 12, and 100 mcg and 200 mcg strengths for patients 12 and older.[34]
• Combination Products: In line with global asthma management guidelines, Mometasone Furoate is co-formulated with the long-acting beta2-agonist (LABA) formoterol in products such as Dulera® and Zenhale®.[1] This combination of an inhaled corticosteroid (ICS) and a LABA is a standard treatment approach for patients whose asthma is not adequately controlled on an ICS alone.

[Summary of Major Clinical Trials for Nasal Mometasone Furoate]

Trial Identifier	Phase	Indication	Patient Population (Age)	Comparator(s)	Key Finding/Purpose	Source(s)
NCT01165424	3	Perennial Allergic Rhinitis (PAR)	Pediatric (Age unspecified)	Placebo	Evaluate long-term safety and efficacy in children.	28
NCT00783224	3	Perennial Allergic Rhinitis (PAR)	Adults & Adolescents	Fluticasone Propionate	Comparative study of efficacy versus another leading intranasal steroid.	28
NCT00733005	3	Seasonal Allergic Rhinitis (SAR)	Adults & Adolescents	Placebo	Efficacy in relieving nasal congestion associated with SAR.	29
NCT00817050	4	Allergic Rhinitis (AR)	Adults & Adolescents	Fluticasone Propionate (scented)	Patient preference study for unscented mometasone vs. scented fluticasone.	31
NCT01470053	3	Perennial Allergic Rhinitis (PAR)	Adults & Adolescents	Azelastine, Placebo	Efficacy of a mometasone/azelastine combination spray vs. monotherapies.	28
NCT00731185	3	Nasal Polyps	Adults (≥18 years)	Placebo	Efficacy for treating nasal polyps after surgery.	32
NCT01386125	3	Nasal Polyps	Adults (≥18 years)	Placebo	Efficacy and safety for the treatment of nasal polyps.	32

Safety, Tolerability, and Risk Management

The safety profile of Mometasone Furoate is well-characterized and is generally favorable, particularly due to its low systemic bioavailability. However, as with all corticosteroids, there are potential local and systemic risks that require careful management and patient monitoring.

[Adverse Effect Profile by Formulation]

Adverse effects are most often localized to the site of application and vary by formulation.

• Nasal: The most frequently reported adverse events are typically mild to moderate and localized. These include headache, viral upper respiratory infections, pharyngitis (sore throat), epistaxis (nosebleeds), and cough.[1] More serious, though rare, local effects include nasal septum perforation and localized infections of the nose and pharynx with Candida albicans.[12]
• Topical: Common local reactions include a transient burning or stinging sensation, itching (pruritus), and dryness at the application site.[1] With prolonged or inappropriate use, more significant dermatological effects can occur, such as skin atrophy (thinning), striae (stretch marks), telangiectasias (spider veins), changes in skin pigmentation, acneiform eruptions, and folliculitis.[17]
• Inhaled: The most characteristic local side effect is oropharyngeal candidiasis, a fungal infection commonly known as thrush. The risk of this can be substantially mitigated by having the patient rinse their mouth with water and spit after each use.[17] Dysphonia (hoarseness) can also occur.[17]

[Systemic Effects and Risk of HPA Axis Suppression]

The primary safety concern for any corticosteroid therapy is the potential for systemic absorption to cause iatrogenic Cushing's syndrome and suppression of the Hypothalamic-Pituitary-Adrenal (HPA) axis. The HPA axis is the body's natural stress response system, and its suppression can lead to adrenal insufficiency, a potentially life-threatening condition. While Mometasone Furoate is engineered to minimize this risk, it is not zero.

• Risk Factors: The likelihood of developing systemic adverse effects is dose- and duration-dependent. Key risk factors include:

1. High Doses: Using dosages that exceed prescribing recommendations.[14]
2. Prolonged Therapy: Long-term, continuous use without breaks.[20]
3. Occlusion (Topical): Applying the topical product under an occlusive dressing or to large body surface areas.[17]
4. Drug Interactions: Concomitant use of potent CYP3A4 inhibitors, which block the drug's metabolism.[14]
5. Sensitive Populations: Young children are particularly susceptible due to their higher body surface area to mass ratio.[17]

• Clinical Manifestations: Symptoms of adrenal suppression can be non-specific and include profound fatigue, weakness, nausea, vomiting, dizziness, hypotension, and weight loss.[20] Chronic overuse can lead to the classic signs of hypercorticism, such as facial rounding, central obesity, and hyperglycemia.[2]
• Monitoring: For patients with multiple risk factors, particularly those on long-term, high-dose therapy, periodic evaluation for HPA axis suppression via tests like the ACTH stimulation test may be warranted.[17]

[Use in Special Populations]

Careful consideration is required when prescribing Mometasone Furoate to vulnerable populations.

• Pediatrics: This population requires special attention and monitoring.
• Growth Velocity: A well-documented class effect of inhaled corticosteroids is the potential for a reduction in linear growth velocity in children. This has been reported with Mometasone Furoate and may be around 1 cm per year, though the long-term effect on final adult height is unknown.[2] It is imperative that pediatric patients be titrated to the lowest effective dose to control their symptoms, and their growth should be monitored routinely.[2]
• Increased Systemic Susceptibility: Due to their larger skin surface area to body mass ratio, infants and children are at a greater risk of absorbing systemically significant amounts of topical corticosteroids, making them more prone to HPA axis suppression and other systemic effects.[17]
• Pregnancy and Lactation:
• Pregnancy: Mometasone Furoate is classified as Pregnancy Category C. There are no or limited data in pregnant women. Animal reproduction studies have shown fetal toxicity at doses at or above the maximum recommended human dose. Therefore, it should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus. Infants born to mothers who received significant doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism.[2]
• Lactation: It is not known whether Mometasone Furoate is excreted in human milk. Since other corticosteroids are, and systemically administered corticosteroids can appear in breast milk and potentially cause untoward effects like growth suppression, caution should be exercised when administering to a nursing mother.[2]
• Hepatic Impairment: Since the systemically absorbed fraction of the drug is cleared by hepatic metabolism, patients with moderate to severe hepatic impairment may have reduced clearance. This could lead to accumulation and an increased risk of systemic side effects. The drug should be used with caution in this population.[2]

[Contraindications and Precautions]

• Contraindications: The primary contraindication is a history of known hypersensitivity to Mometasone Furoate or any of the excipients in the formulation.[1] Additionally, the Asmanex® Twisthaler® is contraindicated in patients with a severe allergy to milk proteins, as the powder formulation contains lactose.[34]
• Precautions:
• Impaired Wound Healing: Due to the inhibitory effect of corticosteroids on wound healing, the nasal spray should not be used in patients with recent nasal septal ulcers, nasal surgery, or nasal trauma until healing is complete.[14]
• Ocular Effects: Long-term use of corticosteroids via nasal or inhaled routes has been associated with the development of glaucoma and cataracts. Patients who develop visual changes or who are on long-term therapy should be considered for referral to an ophthalmologist for monitoring.[1]
• Infections: Corticosteroids can suppress the immune system and increase susceptibility to infections or mask their symptoms. The drug should be used with caution in patients with active or quiescent tuberculosis, or untreated systemic fungal, bacterial, viral, or parasitic infections, including ocular herpes simplex.[12]

Clinically Significant Drug-Drug Interactions

The potential for drug-drug interactions with Mometasone Furoate is almost entirely dictated by its metabolic pathway.

[The Central Role of CYP3A4]

The fraction of Mometasone Furoate that is absorbed into the systemic circulation is extensively metabolized in the liver, primarily by the Cytochrome P450 3A4 (CYP3A4) enzyme isoform.[12] This makes CYP3A4 the focal point for clinically relevant interactions.

The clinical significance of a CYP3A4-mediated interaction is directly proportional to the systemic bioavailability of the specific Mometasone Furoate formulation being used. When an inhibitor of CYP3A4 is co-administered, it blocks the metabolism of mometasone, leading to an increase in its plasma concentration and a prolonged half-life. The magnitude of this effect, and thus the clinical risk, depends on the initial systemic load. For topical and nasal formulations, where bioavailability is less than 1%, the absolute increase in systemic exposure is likely to be small and may not be clinically significant for most patients. However, for the inhaled formulations, which have a systemic bioavailability of around 11%, the same degree of enzymatic inhibition will result in a much larger increase in systemic exposure, elevating the risk of dose-related adverse effects like HPA axis suppression. Therefore, the greatest clinical vigilance is required when co-prescribing inhaled Mometasone Furoate with a potent CYP3A4 inhibitor.

[Interaction with Strong CYP3A4 Inhibitors]

• Interacting Drugs: This class includes potent inhibitors such as the azole antifungals (ketoconazole, itraconazole), certain macrolide antibiotics (clarithromycin), and several HIV protease inhibitors (ritonavir, nelfinavir, atazanavir) and boosters (cobicistat).[22]
• Clinical Effect: Co-administration of these drugs with Mometasone Furoate can significantly inhibit its metabolism, leading to increased serum concentrations and a heightened risk of systemic corticosteroid adverse effects, including Cushing's syndrome and adrenal suppression.[14]
• Management: The universal recommendation is to use Mometasone Furoate with caution when co-administered with a strong CYP3A4 inhibitor.[46] For nasal and topical formulations, this typically involves close monitoring for any signs of systemic effects.[12] For inhaled formulations, where the risk is greater, clinicians should strongly consider alternative therapies. If co-administration is deemed medically necessary, patients must be monitored meticulously for evidence of hypercorticism.
• Food Interaction: Grapefruit and grapefruit juice are potent inhibitors of intestinal CYP3A4. Consistent consumption while on Mometasone Furoate therapy can increase systemic exposure and should be avoided.[48]

[Interaction with CYP3A4 Inducers]

• Interacting Drugs: This class includes drugs such as rifampin, carbamazepine, phenobarbital, phenytoin, and the herbal supplement St. John's Wort.[47]
• Clinical Effect: These agents increase the expression and activity of the CYP3A4 enzyme, which can accelerate the metabolism of Mometasone Furoate. This may lead to lower-than-expected plasma concentrations and potentially reduced therapeutic efficacy. This interaction is most likely to be clinically relevant for inhaled Mometasone Furoate, where achieving adequate systemic and local lung concentrations is necessary for asthma control.

[Management of Key Drug Interactions with Mometasone Furoate]

Interacting Agent/Class	Mechanism of Interaction	Clinical Consequence	Management Recommendation	Source(s)
Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir, Clarithromycin)	Inhibition of CYP3A4-mediated metabolism.	Increased plasma concentration of mometasone; increased risk of systemic corticosteroid effects (HPA axis suppression, Cushing's syndrome).	Use with caution. For inhaled forms, consider alternatives or monitor very closely for systemic side effects. For nasal/topical forms, monitor closely.	14
Grapefruit Juice	Inhibition of intestinal CYP3A4.	Increased systemic exposure to mometasone.	Avoid consistent consumption of grapefruit or grapefruit juice during therapy.	48
Strong CYP3A4 Inducers (e.g., Rifampin, Carbamazepine, St. John's Wort)	Induction of CYP3A4-mediated metabolism.	Decreased plasma concentration of mometasone; potential for reduced therapeutic efficacy, especially with inhaled formulations.	Monitor for lack of efficacy. Dose adjustment of mometasone may be necessary.	47

Regulatory and Commercial Landscape

The history of Mometasone Furoate is one of successful drug development by a major pharmaceutical company, followed by a complex and impactful transition to a multi-source generic market that influenced regulatory science.

[Development and Approval History]

• Origin and Development: Mometasone Furoate was first patented in 1981 and introduced for medical use in 1987.[1] The drug was developed by Schering-Plough, which was later acquired by Merck & Co. in 2009.[15] The company's research focused on creating a more stable monohydrate form of the compound for use in aqueous suspensions, which was critical for the development of the nasal spray formulation and was protected by patents such as U.S. Patent No. 6,127,353.[50]
• Key FDA Approvals:
• Elocon® (Topical): The first formulation to be approved, receiving its initial U.S. approval on April 29, 1987, for inflammatory and pruritic skin conditions.[49]
• Nasonex® (Nasal Spray): The original New Drug Application (NDA 20-762) for the treatment of allergic rhinitis was approved in 1997.[30] A supplemental NDA for the treatment of nasal polyps in adults was subsequently approved on December 15, 2004.[15]
• Asmanex® (Inhaled): The Asmanex® Twisthaler® (DPI) was first approved by the FDA for the maintenance treatment of asthma on March 30, 2005. The indication was later expanded to include pediatric patients aged 4-11 on February 4, 2008.[33]

[Generic Competition and Market Evolution]

• The Nasonex® Generic Challenge: The path to generic competition for the highly successful Nasonex® nasal spray was particularly notable. As detailed in the pharmacokinetics section, the negligible systemic absorption of the drug made it impossible to use standard bioequivalence studies. This presented a major scientific and regulatory barrier that protected the brand-name product from generic competition for many years after its initial patents would have otherwise allowed it.[16]
• Regulatory Innovation and Impact: The FDA's eventual approval of the first generic version from Apotex in March 2016 was a watershed moment.[16] It was made possible by the agency's acceptance of a novel "weight-of-evidence" approach. This approach relied on sophisticated in vitro characterization methods, including Morphologically-Directed Raman Spectroscopy (MDRS), to demonstrate that the generic product was pharmaceutically equivalent to the brand-name drug, in lieu of in vivo data.[16] This decision not only opened the market for generic mometasone nasal spray but also established a new regulatory pathway for future complex generic products that act locally without significant systemic absorption.
• Market Impact and Lifecycle Management: The availability of generic Mometasone Furoate in all its forms has significantly expanded patient access and reduced healthcare costs. Its widespread use is reflected in its ranking as the 311th most commonly prescribed medication in the United States in 2022.[1] In parallel, the development of branded, fixed-dose combination products like Dulera® (mometasone/formoterol) and Ryaltris® (mometasone/olopatadine) represents a classic pharmaceutical lifecycle management strategy. These products offer added clinical benefits or convenience, creating new intellectual property and extending the commercial life of the mometasone franchise beyond the patent expiry of the original single-agent products.

Conclusion

Mometasone Furoate stands as a prime example of successful rational drug design in the field of steroidal anti-inflammatory therapy. Through targeted chemical modifications—specifically the 17α-furoate esterification and chlorination—its developers created a molecule with an optimized therapeutic index, balancing high-potency local action at the glucocorticoid receptor with minimal systemic bioavailability. This fundamental characteristic has enabled its formulation into versatile and effective treatments for a triad of common inflammatory diseases: dermatoses, allergic rhinitis, and asthma.

Its pharmacokinetic profile, defined by low systemic absorption and rapid hepatic clearance via CYP3A4, is the key to its generally favorable safety profile. However, this same metabolic pathway creates a vulnerability to drug-drug interactions with potent CYP3A4 inhibitors, a risk that is most pronounced with the inhaled formulation due to its higher relative bioavailability. Furthermore, its use in special populations, particularly children, requires careful dose titration and monitoring to mitigate the class-wide risk of systemic effects, such as HPA axis suppression and reduced growth velocity.

The regulatory history of Mometasone Furoate, especially the journey to generic approval for its nasal spray formulation, is a compelling narrative of scientific innovation driving policy. The challenges posed by its local action and negligible systemic absorption necessitated a paradigm shift at the FDA, leading to the validation of advanced in vitro methods for bioequivalence testing. This has had a lasting impact on the approval pathway for other complex generic drugs.

In conclusion, Mometasone Furoate is a mature, well-characterized, and indispensable therapeutic agent. Its clinical legacy is built on a foundation of potent local efficacy and a favorable safety profile, while its commercial and regulatory history highlights the dynamic interplay between pharmaceutical science, market forces, and the evolution of regulatory standards. For clinicians, its effective use hinges on a clear understanding of its formulation-specific applications, adherence to approved indications and dosages, and vigilance for potential risks associated with long-term use, pediatric populations, and drug interactions.

Works cited

1. Mometasone - Wikipedia, accessed July 18, 2025, https://en.wikipedia.org/wiki/Mometasone
2. Mometasone furoate: Uses, Interactions, Mechanism of Action ..., accessed July 18, 2025, https://go.drugbank.com/drugs/DB14512
3. Mometasone Furoate | C27H30Cl2O6 | CID 441336 - PubChem, accessed July 18, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/mometasone%20furoate
4. Mometasone furoate | CAS 83919-23-7 | Tocris Bioscience, accessed July 18, 2025, https://www.tocris.com/products/mometasone-furoate_4115
5. Mometasone furoate = 98 HPLC 83919-23-7 - Sigma-Aldrich, accessed July 18, 2025, https://www.sigmaaldrich.com/US/en/product/sigma/m4074
6. Mometasone Furoate | C27H30Cl2O6 | CID 441336 - PubChem, accessed July 18, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/441336
7. Mometasone Furoate 83919-23-7 | Tokyo Chemical Industry Co., Ltd.(APAC), accessed July 18, 2025, https://www.tcichemicals.com/OP/en/p/M2354
8. Mometasone - brand name list from Drugs.com, accessed July 18, 2025, https://www.drugs.com/ingredient/mometasone.html
9. Mometasone furoate (4115) by Tocris, Part of Bio-Techne, accessed July 18, 2025, https://www.bio-techne.com/cn/p/small-molecules-peptides/mometasone-furoate_4115
10. (PDF) Comparative safety and efficacy of topical mometasone furoate with other topical corticosteroids - ResearchGate, accessed July 18, 2025, https://www.researchgate.net/publication/322985861_Comparative_safety_and_efficacy_of_topical_mometasone_furoate_with_other_topical_corticosteroids
11. (PDF) Mometasone furoate nasal spray: A review of safety and systemic effects, accessed July 18, 2025, https://www.researchgate.net/publication/6414259_Mometasone_furoate_nasal_spray_A_review_of_safety_and_systemic_effects
12. mometasone/intranasal | Uses, Side Effects, Interactions - medtigo, accessed July 18, 2025, https://medtigo.com/drug/mometasone-intranasal/
13. A review of the pharmacology and pharmacokinetics of inhaled ..., accessed July 18, 2025, https://pubmed.ncbi.nlm.nih.gov/11589253/
14. Mometasone (Nasal) | Drug Lookup | Pediatric Care Online - AAP Publications, accessed July 18, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5932/Mometasone-Nasal
15. 20-762/S023 - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2004/020762Orig1s023_FINAL_corrected.pdf
16. FDA Embraces Emerging Technology for Bioequivalence Evaluation of Locally Acting Nasal Sprays, accessed July 18, 2025, https://www.fda.gov/media/97705/download
17. Elocon (mometasone topical) dosing, indications, interactions, adverse effects, and more., accessed July 18, 2025, https://reference.medscape.com/drug/elocon-mometasone-topical-343513
18. Mometasone Furoate - FDA Approval - MedPath, accessed July 18, 2025, https://trial.medpath.com/drug/approvals/fda/ce683ebd9654875b
19. HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights ..., accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019625s026lbl.pdf
20. Mometasone (topical application route) - Side effects & dosage - Mayo Clinic, accessed July 18, 2025, https://www.mayoclinic.org/drugs-supplements/mometasone-topical-application-route/description/drg-20073837
21. Mometasone topical: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed July 18, 2025, https://www.webmd.com/drugs/2/drug-5904/mometasone-topical/details
22. Mometasone furoate: Uses, Side Effects, FAQs & More - GoodRx, accessed July 18, 2025, https://www.goodrx.com/mometasone/what-is
23. Clinical Policy: Mometasone (Nasonex) - Superior HealthPlan, accessed July 18, 2025, https://www.superiorhealthplan.com/content/dam/centene/Superior/policies/pharmacy-policies/Mometasone%20(Nasonex)%20(HIM.PA.93)%20(PDF).pdf
24. Nasonex 50 micrograms/actuation Nasal Spray, Suspension - Summary of Product Characteristics (SmPC) - (emc) | 1663, accessed July 18, 2025, https://www.medicines.org.uk/emc/product/1663/smpc
25. Nasonex 24HR Allergy: Uses, Dosage & Side Effects - Drugs.com, accessed July 18, 2025, https://www.drugs.com/nasonex.html
26. Mometasone (EENT) Monograph for Professionals - Drugs.com, accessed July 18, 2025, https://www.drugs.com/monograph/mometasone-eent.html
27. NASONEX® (mometasone furoate monohydrate) nasal spray - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020762s056lbl.pdf
28. Mometasone furoate Completed Phase 3 Trials for Perennial Allergic Rhinitis (PAR) Treatment - DrugBank, accessed July 18, 2025, https://go.drugbank.com/drugs/DB14512/clinical_trials?conditions=DBCOND0058482&phase=3&purpose=treatment&status=completed
29. Mometasone furoate Completed Phase 3 Trials for Allergic Rhinitis (AR) Treatment, accessed July 18, 2025, https://go.drugbank.com/drugs/DB14512/clinical_trials?conditions=DBCOND0053380&phase=3&purpose=treatment&status=completed
30. 20762-S001 Nasonex Approval - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/20762-S001_Nasonex.pdf
31. Mometasone furoate Completed Phase 4 Trials for Allergic Rhinitis (AR) Treatment, accessed July 18, 2025, https://go.drugbank.com/drugs/DB14512/clinical_trials?conditions=DBCOND0053380&phase=4&purpose=treatment&status=completed
32. Mometasone furoate Completed Phase 3 Trials for Nasal Polyps Treatment - DrugBank, accessed July 18, 2025, https://go.drugbank.com/drugs/DB14512/clinical_trials?conditions=DBCOND0004147&phase=3&purpose=treatment&status=completed
33. Asmanex (mometasone furoate) FDA Approval History - Drugs.com, accessed July 18, 2025, https://www.drugs.com/history/asmanex.html
34. ASMANEX® HFA (mometasone furoate) Inhalation Aerosol 50 mcg, 100 mcg, 200 mcg & ASMANEX® TWISTHALER® (mometasone furoate inhalation powder) 110 mcg, 220 mcg, accessed July 18, 2025, https://www.asmanex.com/
35. ASMANEX® HFA (mometasone furoate) Inhalation Aerosol 50 mcg, 100 mcg, 200 mcg, accessed July 18, 2025, https://www.asmanex.com/asmanex-hfa/
36. Dosing - asmanex hfa - Organon Pro, accessed July 18, 2025, https://organonpro.com/en-us/product/asmanex-hfa/dosing/
37. ASMANEX® TWISTHALER® (mometasone furoate inhalation powder) 110 mcg, 220 mcg, accessed July 18, 2025, https://www.asmanex.com/asmanex-twisthaler/
38. Mometasone (inhalation route) - Side effects & dosage - Mayo Clinic, accessed July 18, 2025, https://www.mayoclinic.org/drugs-supplements/mometasone-inhalation-route/description/drg-20067282
39. Asmanex HFA Dosage Guide - Drugs.com, accessed July 18, 2025, https://www.drugs.com/dosage/asmanex-hfa.html
40. Mometasone formoterol: uses, dosing, warnings, adverse events, interactions - MedCentral, accessed July 18, 2025, https://www.medcentral.com/drugs/monograph/154342-305045/mometasone-formoterol-inhalation
41. Side effects of mometasone nasal spray - NHS, accessed July 18, 2025, https://www.nhs.uk/medicines/mometasone-nasal-spray/side-effects-of-mometasone-nasal-spray/
42. Mometasone Nasal Spray: Package Insert / Prescribing Info - Drugs.com, accessed July 18, 2025, https://www.drugs.com/pro/mometasone-nasal-spray.html
43. Side effects of mometasone for skin - NHS, accessed July 18, 2025, https://www.nhs.uk/medicines/mometasone-for-skin/side-effects-of-mometasone-for-skin/
44. Mometasone (Topical) Monograph for Professionals - Drugs.com, accessed July 18, 2025, https://www.drugs.com/monograph/mometasone-topical.html
45. Mometasone Interactions Checker - Drugs.com, accessed July 18, 2025, https://www.drugs.com/drug-interactions/mometasone.html
46. Mometasone (Inhalation) - Asmanex HFA | Davis's Drug Guide, accessed July 18, 2025, https://nursing.unboundmedicine.com/nursingcentral/view/Davis-Drug-Guide/110776/all/mometasone__inhalation_
47. Drug Interactions with CYP3A4: An Update - Pharmacy Times, accessed July 18, 2025, https://www.pharmacytimes.com/view/drug-interactions-with-cyp3a4-an-update
48. Mometasone Furoate Food, Alcohol, Supplements and Drug Interactions, accessed July 18, 2025, https://www.wellrx.com/mometasone-furoate/lifestyle-interactions/
49. Mometasone Furoate - Drug Targets, Indications, Patents - Patsnap Synapse, accessed July 18, 2025, https://synapse.patsnap.com/drug/322626bfed074a1d80345c157653fda9
50. Process for making mometasone furoate monohydrate - Justia Patents, accessed July 18, 2025, https://patents.justia.com/patent/6180781
51. Schering-Plough - Wikipedia, accessed July 18, 2025, https://en.wikipedia.org/wiki/Schering-Plough
52. US6127353A - Mometasone furoate monohydrate, process for making same and pharmaceutical compositions - Google Patents, accessed July 18, 2025, https://patents.google.com/patent/US6127353A/en
53. Mometasone Furoate Nasal Spray, 50 mcg. - accessdata.fda.gov, accessed July 18, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/091161Orig1s000ltr.pdf
54. Generic MOMETASONE FUROATE INN entry, pharmaceutical patent expiration information and freedom to operate - DrugPatentWatch, accessed July 18, 2025, https://www.drugpatentwatch.com/p/generic-api/MOMETASONE+FUROATE